:::

關於癌醫

:::

院長_楊志新

楊志新院長

楊志新James Chih-Hsin Yang

基礎腫瘤醫學臨床腫瘤醫學癌症新治療新藥物研發肺癌精準標靶治療研發肺癌標靶及免疫治療抗藥性研究新藥臨床試驗科學及實踐

  • 國立臺灣大學醫學院附設醫院 癌醫中心分院 院長 2021/06-迄今
    國立臺灣大學醫學院 癌症研究中心 主任 2021/08-迄今
    國立臺灣大學   講座教授 2021/08-迄今
    國立臺灣大學醫學院 腫瘤醫學研究所 教授 2009/08-迄今
    國立臺灣大學醫學院 轉譯醫學博士學位學程 合聘教授 2012/08-迄今
    國立臺灣大學醫學院 臨床藥學研究所 合聘教授 2008/08-迄今
    國立臺灣大學醫學院 臨床醫學研究所 合聘教授 2012/08-迄今
    國立臺灣大學醫學院附設醫院 腫瘤醫學部 兼職主治醫師 2020/08-迄今
  • 國立臺灣大學醫學院 癌醫中心醫院 院長 2020/08-2021/05
    國立臺灣大學醫學院 腫瘤醫學研究所 所長 2015/08-2021/07
    國立臺灣大學醫學院附設醫院 腫瘤醫學部 部主任 2015/08-2020/07
    國立臺灣大學醫學院附設醫院 癌症防治中心 主任 2016/04-2020/07
    國立臺灣大學醫學院附設醫院 醫學研究部 主任 2013/08-2016/07
    國立臺灣大學醫學院 癌症研究中心 主任 2009/08-2015/07
    國立臺灣大學 臨床醫學研究所 副教授 2006/08-2008/07
    國立臺灣大學 臨床藥學研究所 副教授 2006/08-2008/07
    國立臺灣大學 醫學系及臨床藥學研究所 臨床副教授 2004/08-2006/07
    國立臺灣大學 醫學系及臨床藥學研究所 臨床助理教授 2000/08-2004/07
    國立臺灣大學醫學院附設醫院 腫瘤醫學部 主治醫師 1995/08-2020/07
    國立臺灣大學 醫學系 臨床講師 1995/02-2020/07
    美國國家癌症研究中心 腫瘤內科部 臨床醫師 1993/09-1995/08
    美國國家癌症研究中心 腫瘤內科部 交換學者 1992/07-1993/08
    國立臺灣大學醫學院附設醫院 內科 住院醫師 1988/07-1992/06
  • 國立台灣大學 臨床醫學研究所 博士 1996/09-2000/01
    國立臺灣大學 醫學系 學士 1979/09-1986/06
  • 證書 字號  
    醫師證書 醫字第014508號 1986/12/8
    內科專科醫師證書 內專醫字第003113號 2010/1/18
    中華民國腫瘤內科專科醫師證書 中腫內專醫證字第85002號 2014/11/9
    台灣肺癌學會肺癌專科醫師證書 台肺癌專證字第005號 2004/4/9
  • 獎助名稱 獲獎時間
    教育部第24屆國家講座主持人獎 2021/2-2024/1
    傑出人才講座 2019/8-2021/1
    第62屆教育部學術獎 2018
    科技部傑出研究獎 2015/8-2018/7
    第二十二屆東元獎 2015
    國科會傑出研究獎 2012/8-2015/7
    小林癌症化學治療研究獎 2012
    臺大醫院 傑出研究獎 2012
    徐千田癌症研究傑出獎, Chinese Oncology Society 2009
    Poster Award, Joint Cancer Society Annual Meeting, Taiwan, May 1999, 2005
    Research Award, National Science Council, 1996, 1999, 2000, 2001,2002,2003,2004,2005, 2006
  • 參與研究計畫名稱 計畫內
    擔任工作    		 起迄年月 補助或
    委託機構    		 計畫編號 申請(執行)
    情形
    科技部特約研究員計畫 主持人

    2021/08~

    2024/07

    		 科技部   執行中
    國立台灣大學高等教育深耕計畫特色領域研究中心【子計畫三_癌症】 主持人 2020/01/01~
    2020/12/31    		 教育部 109L901403 已結案
    109年度「第3期癌症研究癌症中心計畫-臺大醫院建置癌症卓越研究體系第三期(107-110年)計畫」 主持人 2020/01/01~
    2020/12/31    		 衛生福利部國民健康署 MOHW 109-TDU-B-211-134017 已結案
    109年全方位癌症防治策進計畫 共同主持人 2020/01/01~
    2020/12/31    		 衛生福利部國民健康署 補助案無案號 已結案
    臺灣肺癌臨床試驗合作聯盟 IV 主持人 2020/05/01~
    2021/04/30    		 科技部 109-2321-B-002-036- 已結案
    表皮生長因子接受器突變肺癌產生T790M或非T790M抗藥性之細胞演化機轉 主持人 2018/08/01~
    2021/07/31    		 科技部 107-2314-B-002-220-MY3 已結案
    精準醫學研究中心(3/5) 共同主持人 2020/03/01~
    2021/02/28    		 科技部 109-2634-F-002-043- 已結案
    發展並測試病人面對癌症試驗的「關係自主決策溝通模式」 共同主持人 2020/08/01~
    2021/07/31    		 科技部 109-2314-B-006-073- 已結案
    CD73的表現在EGFR突變肺癌的調控機轉探討 共同主持人 2019/08/01~
    2022/07/31    		 科技部 108-2314-B-002-095-MY3 執行中
    以溝通指引落實癌症臨床試驗知情同意並提升病人自主決策能力：瞭解影響因素、指引建立與評價成效 共同主持人 2017/08/01~
    2020/10/31    		 科技部 106-2314-B-006-052-MY3 已結案
    國立台灣大學高等教育深耕計畫特色領域研究中心【子計畫三_癌症】 主持人 2019/01/01~
    2019/12/31    		 教育部 108L901403 已結案
    108年全方位癌症防治策進計畫 共同主持人 2019/01/01~
    2019/12/31    		 衛生福利部國民健康署 補助案無案號 已結案
    108年度「第3期癌症研究癌症中心計畫-臺大醫院建置癌症卓越研究體系第三期(107-110年)計畫」 主持人 2019/03/21~
    2019/12/31    		 衛生福利部國民健康署 MOHW108-TDU-B-211-124017 已結案
    臺灣肺癌臨床試驗合作聯盟 III 主持人 2019/05/01~
    2020/04/30    		 科技部 108-2321-B-002-041- 已結案
    精準醫學研究中心(2/5) 共同主持人 2010/03/01~
    2020/04/30    		 科技部 1108-3017-F-002-004- 已結案
    107年癌症防治品質精進計畫 共同主持人 2018/01/01~
    2018/12/31    		 衛生福利部國民健康署 採購案號：A1061223 已結案
    國立台灣大學高等教育深耕計畫特色領域研究中心 精準醫學研究中心【子計畫三_癌症】 主持人 2020/01/01~
    2020/12/31    		 教育部 107L90140-3 已結案
    臺灣肺癌臨床試驗合作聯盟 II 主持人 2018/05/01~
    2019/04/30    		 科技部 107-2321-B-002-032- 已結案
    臺灣癌症早期臨床試驗合作聯盟 II 共同主持人 2018/05/01~
    2019/04/30    		 科技部 107-2321-B-002-033- 已結案

  • (A) 期刊論文 (*corresponding author)(近三年內)

    1. Yang JC*, Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Hozak RR, Nguyen TS, Zhang WL, Enatsu S, Puri T, Orlando M. A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutation: Final Overall Survival and Biomarker Analysis. J Thorac Oncol. 2020 Jan;15(1):91-100 (corresponding author)*
    2. Hsu CC, Liao BC, Liao WY, Markovets A, Stetson D, Thress K, Chih-Hsin Yang J* .Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer. J Thorac Oncol. 2020 Jan;15(1):50-61. (corresponding author)*
    3. Yang JC*, Schuler M, Popat S, Miura S, Heeke S, Park K, Märten A, Kim ES.Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. J Thorac Oncol. 2020 May;15(5):803-815. (corresponding author)*
    4. Hung PS, Huang MH, Kuo YY, Yang JC* The Inhibition of Wnt Restrain KRAS(G12V)-Driven Metastasis in Non-Small-Cell Lung Cancer. Cancers (Basel). 2020 Mar 31;12(4):837. (*Corresponding author)
    5. Yang JC*, Shepherd FA, Kim DW, Lee GW, Lee JS, Chang GC, Lee SS, Wei YF, Lee YG, Laus G, Collins B, Pisetzky F, Horn L. Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report. Journal of Thoracic Oncology 2019 May;14(5):933-936 (*Corresponding author)
    6. Yang JC*, Shirish M. Gadgeel SM, Sequist L, Wu SL, Papadimitrakopoulou VA, Su WC, Fiore J, Saraf S, Raftopoulos , Amita Patnaik A. Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. Journal of Thoracic Oncology 2019 Mar ;14(3):553-559 (*Corresponding author)
    7. Yang JC*. Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment? Lancet Oncol. 2019 May;20(5):602-603. (letter) (*Corresponding author)
    8. Lin CC, Shih JY, Yu CJ, Ho CC, Liao WY, Lee JH, Tsai TH, Su KY, Hsieh MS, Chang YL, Bai YY, Huang D, Thress KS and Yang JC*. Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. Lancet Respiratory Medicine 2018 Feb;6(2):107-116 (*Corresponding author)
    9. Hsu WH, Yang JC*, Mok TS Loong HH. Overview of current systemic management of EGFR-mutant NSCLC. Annals of Oncology 2018 Jan 1;29(suppl_1):i3-i9. (review) (*corresponding author).
    10. Yang JC*, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, Cantarini M, Ghiorghiu S, Jänne PA. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.Journal of Clinical Oncology 2017 Apr 20;35(12):1288-1296 (*corresponding author)
    11. Ahn MJ, Kim DW, Cho BC, Kim SW, Lee JS, Ahn JS, Kim TM, Lin CC, Kim HR, John T, Kao S, Goldman JW, Su WC, Natale R, Rabbie S, Harrop B, Overend P, Yang ZF and Yang JC*. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respiratory Medicine 2017 Nov;5(11):891-902. (*Corresponding author)
    12. Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Thongprasert S, Fukuoka M, Lord S, Marschner I, Tu YK, Gralla RJ, Gebski V, Mok T, James Yang JC*. Gefitinib or erlotinib versus chemotherapy for EGFR mutation-positive lung cancer: individual-patient-data meta-analysis of overall survival. J National Cancer Inst. 2017 Feb 2;109(6). doi: 10.1093/jnci/djw279. (*Corresponding author)
    13. Lee CK, Man J, Lord S, Links M, Gebski V, Mok T, Yang JC* Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis. J Thorac Oncol 2017 Feb;12(2):403-407. (brief report) (*Corresponding author)
    14. Yang JC*, Ou SI, De Petris L, Gadgeel S, Gandhi L, Kim DW, Barlesi F, Govindan R, Dingemans AC, Crino L, Lena H, Popat S, Ahn JS, Dansin E, Golding S, Bordogna W, Balas B, Morcos PN, Zeaiter A, Shaw AT. Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 Oct;12(10):1552-1560 (*Corresponding author).
    15. Yang JC*, Puri T, Orlando M, Cheng Y. Reply to A. Ota et al, Y.H. Kim, and N. Van Der Steen et al. Journal of Clinical Oncology 2017 Feb 20;35(6):694-696. (*corresponding author)
    16. Ma WL, Lin CC, Hsu FM, Lee JM, Chen JS, Hsieh MS, Chang YL, Chao YT, Chang CH, Chih-Hsin Yang J. Clinical Outcomes of Up-front Surgery Versus Surgery After Induction Chemotherapy for Thymoma and Thymic Carcinoma: A Retrospective Study. Clin Lung Cancer. 2019 Nov;20(6):e609-e618. doi: 10.1016/j.cllc.2019.06.011. Epub 2019 Jul 10. (*corresponding author)
    17. Liao BC, Griesing S, Yang JC*. Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients. Ther Adv Med Oncol. 2019 Nov 25;11:1758835919890286. doi: 10.1177/1758835919890286. eCollection 2019. (Review). (*corresponding author)
    18. Wu TH, Hsiue EH, Yang JC*. Opportunities of circulating tumor DNA in lung cancer. Cancer Treat Rev. 2019 Aug;78:31-41 (*corresponding author)
    19. Lee JH, Chen HY, Hsu FM, Chen JS, Liao WY, Shih JY, Yu CJ, Chen KY, Tsai TH, Yang JC*. Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors. Oncologist. 2019 Dec;24(12):e1417-e1425 (*corresponding author)
    20. Wu TH, Hsiue EH, Lee JH, Lin CC, Liao WY, Ho CC, Shih JY, Yu CJ, Yang JC*. Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients. Clin Lung Cancer. 2018 May;19(3):e361-e372. (*corresponding author)
    21. Wu YL, Hirsh V, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Schuler M, Mok T, Yamamoto N, O'Byrne K, Geater SL, Zhou C, Massey D, Märten A, Lungershausen J, Yang JC*. Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). The Patient 2018 Feb;11(1):131-141 (*Corresponding author)
    22. Yang JC*, Mok T, Han B, Orlando M, Puri T, Park K. A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2018 Jan;19(1):27-34 (review) (*corresponding author)
    23. Liao BC, Lin CC, Lee JH, Yang JC. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy. Lung Cancer. 2017 Aug;110:7-13. (corresponding author)
    24. Wu YL*, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Schuler M, Mok T, Yamamoto N, O’Byrne K, Hirsh V, Gibson N, Massey D, Kim M and Yang JC*. EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. Br. J Cancer. 2017 Jan 17;116(2):175-185.  (*Corresponding author)

  • (B) 研討會論文(近三年內)

    Topic Time/Place Conference Name and Sponsor
    Promising novel agents for novel drivers 2019 Dec 8 Osaka The 60th annual meeting for Japanese Lung Cancer Society
    Use of liquid biopsy in non-small cell lung cacner 2019 Nov 24 Singapore ESMO Asia, Colloquium Guardant Health
    Immunotherapy in NSCLC: Most Recent Advances for Stage III and Metastatic NSCLC 2019 Nov 24 Singapore ESMO Asia, a Medscape Live Spotlight Filming, with Harvard Medical School Series
    Newly diagnosed advanced EGFRm NSCLC – what information will help improve our treatment decision? 2019 Nov 23 Singapore ESMO Asia, AZ satellite symposium ESMO
    Constant Changing Landscape of Lung Cancer Treatment 2019 Nov 17 Seoul APECHO Solid Tumor Novartis
    Tumour promoting inflammation (TPI) 2019 Nov 16 Shanghai CANOPY investigator meeting Novartis
    My career path 2019 Nov 10 Tokyo JLCS young investigator training program
    Insights into Mechanisms of Resistance and Characterizing Oncogenic Drivers in ALK+NSCLC 2019 Nov 8 Seoul Korean Medical Oncology Society annual meeting
    Takeda satellite symposium  
    Evolution in the treatment landscape of non-small cell lung cancer treatment with ALK gene alterations: Differantiation between ALK inhibitors. 2019 Nov 1 Antalya, Turkey National Immunotherapy and Oncology Congress, Turkey.
    Frontline EGFR TKIs which one to choose? Oct 11-12th 2019 Hanoi, Ho-Chi-Ming City, Vietnam Boehringer Ingelheim
    Lung Cancer Summit, chair Oct 1, 2019, Barcelona, Spain Astrazeneca
    Common options for uncommon mutations Sep 29 2019 Barcelona, Spain, BI satellite symposium ESMO annual congress
    The unmet medical demand and trend of NSCLC immunotherapy Sep 17 2019 Xiamen, China CTIO
    MSD
    When to Switch to a New TKI : Imaging Based Crtieria or Positive Liquid Biopsy? Sep 9, 2019 Barcelona, Spain Scientific symposium
    WCLC
    Paving the Way to Better Outcomes in EGFR-Mutant NSCLC:  Time to Take a Step Further?(Chair) Sep 9 2019 Barcelona, Spain PeerCME
    WCLC
    Integrating Immunotherapy in Stage III NSCLC Disease Management 2019 April 7 Kuala Lumpur National Oncology Summit 2019
    Malaysia Medical Oncology Society
    What's next after patient progresses on EGFR TKIs? 2019 April 7 Kuala Lumpur National Oncology Summit 2019
    Malaysia Medical Oncology Society
    Precision Therapy of Lung Cancer in Immunotherapy Era: Where to go how to go? 2019 March 23 Hong Kong Roche Lung Cancer Club
    EGFR update 2019 March 1 Luzern, Swiss SAMO Interdisciplinary Workshop on Chest Tumors
    Recent advances in biomarker of NSCLC: Role of cell‐free DNA and liquid biopsy 2019 Jan 19 Seoul, Korea Medical Educational Onco Summit: Lung Cancer
    Takeda Oncology
    Keynote: Lung cancer landscape – present and future 2019 Jan 11 Taipei, Taiwan Optimising outcomes in lung cancer through fast and accurate patient selection
    Astrazeneca Diagnostics
    The era of precision medicine with EGFR TKI, Osimertinib: an optimal strategy to manage T790M mutant NSCLC patients 2018 Nov 24 Seoul, Korea 2018 KALC　Korean Association for Lung Cancer international conference
    Targeting acquired resistance to EGFR kinase inhibitors: Beyond T790M mutation 2018 Nov 9 Guangzhou, China PRIMEoncology symposium IASLC Asia Conference on Lung Cancer
    How to overcome TKI resistance? 2018 Nov 9 Guangzhou, China IASLC Asia Conference on Lung Cancer
    MEET the “MET” or “mutMET”
    a “DÉJÀ vu” or a “breakthrough” Invited discussant for GEOMETRY study    		 2018 Oct 19 Munich, Germany ESMO (European Society of Medical Oncology) annual meeting
    ESMO
    Chair of BI symposium 2018 Oct 26 Munich, Germany ESMO (European Society of Medical Oncology) annual meeting
    Boehringer Ingelheim Satellite sympoisum
    High light of non-driver NSCLC treatment in 2018 2018 Oct 14 Wuhan, China Mid-China Lung Cancer Summit
    Tongi University, Wuhan
    Brigatinib for 2nd line treatment of ALK positive NSCLC 2018 Sep 26 Toronto, Canada 19th World Lung Cancer Conference, “Takeda Advisory Board”
    Optimal sequencing of therapy for non-driver lung cancer: chemotherapy + anti-angiogenics 2018 Sep 23 Toronto, Canada 19th World Lung Cancer Conference, “Steering improved outcomes of non-driver mutation lung cancer : progress and challenges”
    Debate on the sequence of EGFR TKI : sequential treatment 2018 Sep 23 Toronto, Canada 19th World Lung Cancer Conference,
    Rapid advances of nonsmall cell lung cancer treatment: perspectives from 2018 2018 Aug 25 Zhengzhou, China 11th International Symposium for Chinese Medicinal Chemists 2018
    Global Strategies for the Treatment of EGFR Mutation Positive Patient 2018 Aug 20,21,22 Sydney, Melbourne BI sponsored symposium in St. Vincent Hospital, Sydney, Melbourne
    Rapid evolving paradigm for advanced nonsmall cell lung cancer treatment 2018 July 27 Bundang, Korea Seoul National University Cancer Cancer 10th year anniversary symposium.
    Global Strategies for the treatment of EGFR mutant NSCLC 2018 July 20 Kobe, Japan Japanese Society of Medical Oncology (JSMO) Annual Meeting
    BI satellite symposium
    1. Acquired Resistance to molecular targeted therapy and strategy for overcoming
    2. Future perspectives of treatment for NSCLC
    		 2018 July 20 Kobe, Japan Japanese Society of Medical Oncology (JSMO) Annual Meeting
    Dose optimization to balance EGFR TKI efficacy and tolerability 2018 July 7, 8 Macao, Hong Kong Macao Oncology Society symposium
    Global Challenges in Conducting MRCT and Interpreting Data 2018 June 24 Boston, USA Drug Information Association annual meeting, Taiwan Townhall meeting
    Clinical Oncologist’s perspectives of Next Generation Sequence 2018 April 13 Geneva, Swiss European Lung Cancer Conference annual meeting, ESMO and IASLC
    Immunotherapy, 2nd line, no IO 2018 March 23 Madrid, Spain IASLC lung cancer immunotherapy meeting, IASLC
    Recent advances in EGFR mutant NSCLC 2018 March 17 Bangkok, Thailand DSU (discussion on scientific update on lung cancer) Boehringer Ingelheim
    Global Strategies for the Treatment of EGFR Mutation Positive Patient 2018 March 11 Osaka, Japan The 1st International Cancer Research Symposium of Training Plan for Oncology Professionals, Kindai University
    AZD3759 2018 Feb 22 Santa Monica, USA 18th Annual Targeted Therapies of Lung Cancer Meeting, IASLC
    Combination therapies of molecular targeted drugs for lung cancer 2017 Dec 8 Singapore JSMO, Young Investigators training
    Translational Research on lung cancer 2017 Nov 25 Wuhan, China Mid China Lung Cancer Forum
    Deep dive into the lung cancer’s world of immunooncology 2017 Nov 24 Shanghai, China 7th international symoisum on respiratory endoscope and lung cancer
    Development and resistance to 3rd G EGFR TKI 2017 Oct 28 Taipei Joint IASLC TLCS symposium
    Update of the management of EGFR positive NSCLC 2017 Oct 15 Yokohama, Japan World Lung Cancer Conference
    IASLC
    PD1 for EGFR mut patients existing data 2017 Oct 1 Osaka, Japan MSD advisory board
    EGFR TKI, 3 generations 2017 Sep 28 Xiamen CSCO, satellite symposium
    Optimal Clinical application of the three generations of EGFR TKI 2017 Sep 27 Xiamen CSCO annual meeting
    AURA studies, how to perform translational research 2017 Sep 17 Shanghai CSCO young investigators training
    Current Paradigms and future trends in EGFR mutation driven NSCLC treatments 2017 Aug 20 Singapore Multidisciplinary Lung Cancer Conference
    Precision Medicine its current status and possibilities for future collaborations 2017 July 27 Kobe, Japan Japanese Society of Medical Oncology
    Targeting Resistance to immunotherapy (Modulator) 2017 June 18 Shanghai, China APECHO
    Novartis
    Recent updates in treatment of ALK+ NSCLC 2017 May 24 Kyungju, Korea Korean Association for Lung Cancer
    PDL1 agents as monotherapy in 2L treatment of NSCLC 2017 June 3, Chicago Satellite Symposium, ASCO, MSD
    AURA studies 2017 May 27 Guangzhou China Osimertinib launch symposium
    Astrazeneca
    Latest update of targeted therapies for lung cancers with rare actionable mutations 2017 May 20 Hong Kong Hong Kong International Oncology Forum 2017, University of Hong Kong
    AURA studies 2017 May 15 Chengzhou China Osimertinib launch symposium \
    Astrazeneca
    Management beyond 1st Line progression with targeted therapies 2017 May 12 Seoul, Korea Discussions on Scientific Updates
    Boehringer Ingelheim
    Systemic treatment for brain metastasis 2017 May 5 Geneva, Swiss European Lung Cancer Conference
    Targeting EGFR T790M
    in mEGFR advanced NSCLC    		 2017 April 2 Brisbane, Melbourne, Sydney Astrazeneca, Australia
    Targeting ALK in Advanced NSCLC 2017 March 19, Hongkong HK and Macao Annual Scientific Meeting 2017, Hong Kong
    Advance of precision treatment in NSCLC——The story of third-generation TKI 2017 March 10 Shaoxing   Precision Medicine, CSCO
    AZD3759 2017 Feb 22, Santa Monica, USA   17th Annual Targeted Therapies of Lung Cancer Meeting IASLC
    The next generation of TKI and Immuno-oncology 2017 Feb 19 Tokyo, Japan 2017 Current Trends in Immuno-Oncology
    1. The value of cfDNA testing in clinical practice: the oncologist perspective
    2. Exploring treatment of patients with lung cancer harbouring actionable mutations
    		 2017 Feb 8, Rome Italy ONE4U Pan-tumour Scientific Exchange Meeting Astrazeneca



最後更新：

:::

將另開新視窗，連結至臺大癌醫以外的網站！

回到最上面